‘Real-life’ experience with direct-acting antiviral agents for HCV after kidney transplant

‘Real-life’ experience with direct-acting antiviral agents for HCV after kidney transplant

Introductions and Objectives: The introduction of direct-acting antiviral (DAA) agents promises to change dramatically the management of hepatitis C in kidney transplant recipients, a patient group where the treatment of hepatitis C is historically challenging. The purpose of the current study was t...

Full description

Bibliographic Details
Main Authors:	Fabrizio Fabrizi, Cristina Alonso, Ana Palazzo, Margarita Anders, Maria Virginia Reggiardo, Hugo Cheinquer, Maria Grazia Videla Zuain, Sebastian Figueroa, Manuel Mendizabal, Marcelo Silva, Ezequiel Ridruejo
Format:	Article
Language:	English
Published:	Elsevier 2021-11-01
Series:	Annals of Hepatology
Subjects:	Antiviral agents Chronic kidney disease Hepatitis C Kidney transplant Viral response
Online Access:	http://www.sciencedirect.com/science/article/pii/S1665268121000363

Similar Items

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
by: Fabrizio Fabrizi, et al.
Published: (2019-10-01)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
by: Andrea Angeletti, et al.
Published: (2019-02-01)

Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease
by: Fabrizio Fabrizi, et al.
Published: (2022-11-01)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
by: Fabrizio Fabrizi, et al.
Published: (2021-04-01)

Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis
by: Zepei Feng, et al.
Published: (2022-05-01)

Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
by: Elena Laura Iliescu, et al.
Published: (2020-01-01)

Selection dynamics of HCV genotype 3 resistance-associated substitutions under direct-acting antiviral therapy pressure
by: João Paulo Vilela Rodrigues, et al.
Published: (2022-11-01)

Interactions between Immunosuppressive Therapy and Direct-Acting Antivirals in Kidney Transplant Recipient with Hepatitis C Infection
by: Paolo Carta, et al.
Published: (2020-05-01)

Antiviral Effects and Underlying Mechanisms of Probiotics as Promising Antivirals
by: Yanjin Wang, et al.
Published: (2022-06-01)

An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease
by: Fabrizio Fabrizi, et al.
Published: (2021-10-01)

HCV-Specific T Cell Responses During and After Chronic HCV Infection
by: Hendrik Luxenburger, et al.
Published: (2018-11-01)

Successful outcome of transplanting a kidney from a HCV-positive deceased donor into a HCV-negative recipient
by: Zaheer Amin Virani, et al.
Published: (2018-01-01)

Tomoelastography for Longitudinal Monitoring of Viscoelasticity Changes in the Liver and in Renal Allografts after Direct-Acting Antiviral Treatment in 15 Kidney Transplant Recipients with Chronic HCV Infection
by: Stephan R. Marticorena Garcia, et al.
Published: (2021-02-01)

Shear Wave Elastography for Assessing Liver Stiffness in HCV-Infected Kidney Transplant Recipients after Direct-Acting Antiviral Treatment: A Comparative Study with Magnetic Resonance Elastography
by: Salma Almutawakel, et al.
Published: (2023-12-01)

NOVEL DIRECT ACTING ANTIVIRAL REGIMENS FOR PATIENTS WITH CHRONIC HEPATITIS C AND CHRONIC KIDNEY DISEASE STAGE 3 TO STAGE 5D
by: Nauman Kashif, et al.
Published: (2020-08-01)

Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
by: Nancy Abdel Fattah Ahmed, et al.
Published: (2020-08-01)

Real-World Treatment Patterns of Antiviral Prophylaxis for Cytomegalovirus Among Adult Kidney Transplant Recipients: A Linked USRDS-Medicare Database Study
by: Amit D. Raval, et al.
Published: (2022-08-01)

Corrigendum: Real-World Treatment Patterns of Antiviral Prophylaxis for Cytomegalovirus Among Adult Kidney Transplant Recipients: A Linked USRDS-Medicare Database Study
by: Amit D. Raval, et al.
Published: (2024-02-01)

Direct-acting Antivirals in Kidney Transplant Patients: Successful Hepatitis C Treatment and Short Term Reduction in Urinary Protein/Creatinine Ratios
by: Michael R. Goetsch, et al.
Published: (2017-09-01)

Ophthalmic antiviral chemotherapy : An overview
by: Athmanathan Sreedharan, et al.
Published: (1997-01-01)

Successful Treatment of Hepatitis C Virus Infection Using Direct-Acting Antiviral Agents (DAAs) in Adolescents with Kidney Transplantation: A Case Series
by: Ambarsari CG, et al.
Published: (2020-06-01)

Editorial: Plant products for antiviral therapeutics
by: Anirban Mandal, et al.
Published: (2022-10-01)

Antiviral Agents
by: Firdevs AKTAŞ
Published: (1997-12-01)

New antiviral agents and new treatments on the horizon for the management of viral hepatitis
by: M. Sönmezoğlu
Published: (2011-12-01)

Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience
by: Mira Atef, et al.
Published: (2022-09-01)

How to use COVID-19 antiviral drugs in patients with chronic kidney disease
by: Ajinath Kale, et al.
Published: (2023-02-01)

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
by: Michael Duerr, et al.
Published: (2019-02-01)

An Update on Hepatocellular Carcinoma in Chronic Kidney Disease
by: Fabrizio Fabrizi, et al.
Published: (2021-07-01)

Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil
by: Hoel Sette-Jr, et al.
Published: (2017-09-01)

Hepatitis C and Its Metabolic Complications in Kidney Disease
by: Fabrizio Fabrizi, et al.
Published: (2017-11-01)

Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals
by: Erica Nicola Lynch, et al.
Published: (2023-03-01)

Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters
by: Mary-Anne Doyle, et al.
Published: (2019-03-01)

Potential Antiviral Action of Alkaloids
by: Frage L. Abookleesh, et al.
Published: (2022-01-01)

Resolution of refractory hepatic hydrothorax in patients with hepatitis C virus cirrhosis after treatment with direct-acting antiviral agents
by: Maged H Hussein, et al.
Published: (2018-01-01)

Case report: Chronic hepatitis C with anti-HCV positive and serum HCV RNA negative
by: Huihui Lu, et al.
Published: (2023-04-01)

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
by: Giuseppe Bruno, et al.
Published: (2017-09-01)

Antiviral Activity of Jamaican Medicinal Plants and Isolated Bioactive Compounds
by: Henry Lowe, et al.
Published: (2021-01-01)

Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals
by: Kazuto Tajiri, et al.
Published: (2023-05-01)

The Outcomes of Direct-acting Antiviral Treatment in 177 Patients with Hepatitis C Virus: A Single-center Experience
by: Ayşin KILINÇ TOKER, et al.
Published: (2023-12-01)

Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin
by: Guillermo Cabrera Álvarez, et al.
Published: (2011-10-01)